Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.

摘要: Bcl-2 proteins are key determinants in the life-death balance. In recent years, this family have been identified as drug targets design of new anti-tumor therapies. Advances knowledge mechanism action anti-apoptotic and pro-apoptotic members enabled development so-called ‘BH3 mimetics’. These compounds act by inhibiting family, imitating function BH3-only subset members. Combinations BH3-mimetics with drugs being evaluated both preclinical models clinical trials. Recent advances these approaches will be reviewed.